Living conditions and health status of populations living in territories impacted by nuclear accidents - Some lessons for developing health surveillance programme.

Chernobyl Ethical values Experts Fukushima Local facilitators Local populations Nuclear accidents Public health Self-help protective actions Well-being

Journal

Environment international
ISSN: 1873-6750
Titre abrégé: Environ Int
Pays: Netherlands
ID NLM: 7807270

Informations de publication

Date de publication:
02 2021
Historique:
received: 01 07 2020
revised: 01 11 2020
accepted: 17 11 2020
pubmed: 29 12 2020
medline: 24 4 2021
entrez: 28 12 2020
Statut: ppublish

Résumé

This paper explores how health concerns of populations living in contaminated areas following radiological accidents can be considered in developing health surveillance. The research was performed in the framework of the SHAMISEN project, and aimed at identifying the impacts on, and challenges associated with, living and social conditions of affected populations. These objectives were achieved through the analysis of specific Case Studies in different situations observed after the Chernobyl accident (Belarus and Norway) and the activities carried out after the Fukushima accident. It incorporates an analysis of testimonies of medical experts and local stakeholders from contaminated territories in Japan within two Case Studies as well as through a dedicated workshop jointly organised with Fukushima Medical University in Japan in March 2016. The analysis addresses the following topics:Thus, this paper outlines key lessons learned from each of these topics, by providing tangibles examples from the analysis of the various Case Studies.

Identifiants

pubmed: 33360722
pii: S0160-4120(20)32249-2
doi: 10.1016/j.envint.2020.106294
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106294

Informations de copyright

Copyright © 2020. Published by Elsevier Ltd.

Auteurs

Mélanie Maître (M)

Nuclear Protection Evaluation Center (CEPN), 28 rue de la Redoute, 92260 Fontenay-aux-Roses, France.

Pascal Croüail (P)

Nuclear Protection Evaluation Center (CEPN), 28 rue de la Redoute, 92260 Fontenay-aux-Roses, France. Electronic address: pascal.crouail@cepn.asso.fr.

Thierry Schneider (T)

Nuclear Protection Evaluation Center (CEPN), 28 rue de la Redoute, 92260 Fontenay-aux-Roses, France.

Yujiro Kuroda (Y)

Research Department, Fukushima Prefectural Centre for Environmental Creation, 10-2 Fukasaku, Miharu Town, Fukushima 963-7700, Japan.

Makoto Miyazaki (M)

Fukushima Medical University (FMU), 1 Hikariga-oka, Fukushima City 960-1295, Japan.

Koichi Tanigawa (K)

FMC (Futaba Medical Center), 817-1 Otsuka, Moto-oka, Futaba Town, 9791151 Fukushima, Japan.

Deborah Oughton (D)

Norwegian University of Life Sciences (NMBU), Faculty of Environmental Sciences and Natural Resource Management/CERAD (Centre for Environmental Radioactivity), P.O. Box 5003, NO-1432 Ås, Norway.

Yevgeniya Tomkiv (Y)

Norwegian University of Life Sciences (NMBU), Faculty of Environmental Sciences and Natural Resource Management/CERAD (Centre for Environmental Radioactivity), P.O. Box 5003, NO-1432 Ås, Norway.

Lavrans Skuterud (L)

Norwegian Radiation and Nuclear Safety Authority (DSA), P. O. Box 329 Skøyen, NO-0213 Oslo, Norway.

Liudmila Liutsko (L)

Barcelona Institute for Global Health (ISGlobal) - Campus MAR, Doctor Aiguader 88, 08003 Barcelona, Spain; CIBERESP, Madrid, Spain.

Sylvie Charron (S)

Radiation Protection and Nuclear Safety Institute (IRSN), BP 17, 92262 Fontenay-aux-Roses Cedex, France.

Christiane Pölz-Viol (C)

Federal Office for Radiation Protection (BfS), Department Radiation Protection and Health, Ingolstaedter Landstr. 1, 85764 Oberschleissheim, Germany.

Ausrele Kesminiene (A)

International Agency for Research on Cancer (IARC), 150 Cours Albert Thomas, 69372 Lyon CEDEX 08, France.

Evgenia Ostroumova (E)

International Agency for Research on Cancer (IARC), 150 Cours Albert Thomas, 69372 Lyon CEDEX 08, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH